HBV-specific T cells in HBV/HIV coinfection
Official title: HBV-specific T cell immunity in HBV/HIV coinfection
Funded at University of Alabama at Birmingham · NIH-11583907 · Data updated 2026-11-12
Researchers are studying how liver-targeted immune cells respond in people living with both HIV and hepatitis B to guide better therapies.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | August 7, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $134,438 |
| NIH project number | 3R37AI179640-04S1 |
| Project ID | NIH-11583907 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults living with HBV, HIV, or HBV/HIV coinfection who are part of the collaborating cohort and able to provide blood and liver samples.
✕Less likely to help
Individuals without HBV or with non-coinfected HIV or HBV may not directly benefit from this specific immunology study.
What this research studies
This project looks at HBV-specific CD4 T cells, which can be affected by HIV, to understand how immune control of HBV might be achieved in coinfected individuals. The study will involve samples from patients in a collaboration with a cohort in Zambia, including blood and liver specimens. Findings could inform future treatments aiming to activate immune responses that clear HBV in people living with HIV. The work is conducted under an NIH grant to advance strategies toward functional cure in HBV/HIV coinfection.
Why it matters
Potential benefit: If successful, the research could identify immune targets and inform therapies that improve HBV control in people with HIV.
How similar studies have gone: Preclinical and translational work has shown HBV-specific T cells relate to control of HBV, but this exact coinfected human cohort study is a more targeted investigation.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Vinikoor, Michael Jeffrey — University of Alabama at Birmingham
- Study coordinator: Vinikoor, Michael Jeffrey
Related research
Other NIH-funded projects on the same topics.
-
IOP and CSF Pressure in Glaucoma Risk
This grant studies how eye pressure and cerebrospinal fluid pressure together influence glaucoma risk and vision loss.
-
Exploring how Down syndrome affects optic nerve health in kids
A study using a mouse model to understand why optic nerve problems are common in children with Down syndrome and how to prevent them.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.